{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:35:54Z","timestamp":1790436954821,"version":"4.1.0"},"reference-count":164,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.5551\/jat.rv17055","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T22:08:28Z","timestamp":1620425308000},"page":"905-925","source":"Crossref","is-referenced-by-count":64,"title":["Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments"],"prefix":"10.5551","volume":"28","author":[{"given":"Shingo","family":"Koyama","sequence":"first","affiliation":[{"name":"Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine"},{"name":"Institute for Biomedical Sciences, Shinshu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsune","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miida","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Cali JJ, Hsieh CL, Francke U, Russell DW: Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem, 1991; 266: 7779-7783","DOI":"10.1016\/S0021-9258(20)89518-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Verrips A, Hoefsloot LH, Steenbergen GC, Theelen JP, Wevers RA, Gabre\u00ebls FJ, van Engelen BG, van den Heuvel LP: Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain, 2000; 123: 908-919","DOI":"10.1093\/brain\/123.5.908"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, Pardo J, Arias M, Ares-Luque A, Duarte J, Mu\u00f1iz-P\u00e9rez S, Sobrido MJ: Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol, 2011; 18: 1203-1211","DOI":"10.1111\/j.1468-1331.2011.03439.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mignarri A, Gallus GN, Dotti MT, Federico A: A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis, 2014; 37: 421-429","DOI":"10.1007\/s10545-013-9674-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Nie S, Chen G, Cao X, Zhang Y: Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis, 2014; 9: 179","DOI":"10.1186\/s13023-014-0179-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Salen G, Steiner RD: Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis, 2017; 40: 771-781","DOI":"10.1007\/s10545-017-0093-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Wong JC, Walsh K, Hayden D, Eichler FS: Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis, 2018; 41: 647-656","DOI":"10.1007\/s10545-018-0152-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Duell PB, Salen G, Eichler FS, DeBarber AE, Connor SL, Casaday L, Jayadev S, Kisanuki Y, Lekprasert P, Malloy MJ, Ramdhani RA, Ziajka PE, Quinn JF, Su KG, Geller AS, Diffenderfer MR, Schaefer EJ: Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. J Clin Lipidol, 2018; 12: 1169-1178","DOI":"10.1016\/j.jacl.2018.06.008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sekijima Y, Koyama S, Yoshinaga T, Koinuma M, Inaba Y: Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet, 2018; 63: 271-280","DOI":"10.1038\/s10038-017-0389-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Berginer VM, Salen G, Shefer S: Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med, 1984; 311: 1649-1652","DOI":"10.1056\/NEJM198412273112601"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ: Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr, 1998; 157: 313-316","DOI":"10.1007\/s004310050818"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S: Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol, 2013; 36: 78-83","DOI":"10.1097\/WNF.0b013e318288076a"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Stelten BML, Huidekoper HH, van de Warrenburg BPC, Brilstra EH, Hollak CEM, Haak HR, Kluijtmans LAJ, Wevers RA, Verrips A: Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start. Neurology, 2019; 92: e83-e95","DOI":"10.1212\/WNL.0000000000006731"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) DeBarber AE, Luo J, Star-Weinstock M, Purkayastha S, Geraghty MT, Chiang JP, Merkens LS, Pappu AS, Steiner RD: A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns. J Lipid Res, 2014; 55: 146-154","DOI":"10.1194\/jlr.P043273"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Salen G: Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism. Ann Intern Med, 1971; 75: 843-851","DOI":"10.7326\/0003-4819-75-6-843"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Bj\u00f6rkhem I, Skrede S, Buchmann MS, East C, Grundy S: Accumulation of 7 alpha-hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: effect of treatment with chenodeoxycholic acid. Hepatology, 1987; 7: 266-271","DOI":"10.1002\/hep.1840070210"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Bhattacharyya AK, Lin DS, Connor WE: Cholestanol metabolism in patients with cerebrotendinous xanthomatosis: absorption, turnover, and tissue deposition. J Lipid Res, 2007; 48: 185-192","DOI":"10.1194\/jlr.M600113-JLR200"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) DeBarber AE, Connor WE, Pappu AS, Merkens LS, Steiner RD: ESI-MS\/MS quantification of 7alpha-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis. Clin Chim Acta, 2010; 41: 43-48","DOI":"10.1016\/j.cca.2009.09.036"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) DeBarber AE, Luo J, Giugliani R, Souza CF, Chiang JP, Merkens LS, Pappu AS, Steiner RD: A useful multi-analyte blood test for cerebrotendinous xanthomatosis. Clin Biochem, 2014; 47: 860-863","DOI":"10.1016\/j.clinbiochem.2014.04.017"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Menkes JH, Schimschock JR, Swanson PD: Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol, 1968; 19: 47-53","DOI":"10.1001\/archneur.1968.00480010065004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Panzenboeck U, Andersson U, Hansson M, Sattler W, Meaney S, Bj\u00f6rkhem I: On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J Lipid Res, 2007; 48: 1167-1174","DOI":"10.1194\/jlr.M700027-JLR200"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) B\u00e5vner A, Shafaati M, Hansson M, Olin M, Shpitzen S, Meiner V, Leitersdorf E, Bj\u00f6rkhem I: On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase. J Lipid Res, 2010; 51: 2722-2730","DOI":"10.1194\/jlr.M008326"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Salen G, Berginer V, Shore V, Horak I, Horak E, Tint GS, Shefer S: Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med, 1987; 316: 1233-1238","DOI":"10.1056\/NEJM198705143162002"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Batta AK, Salen G, Shefer S, Tint GS, Batta M: Increased plasma bile alcohol glucuronides in patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid. J Lipid Res, 1987; 28: 1006-1012","DOI":"10.1016\/S0022-2275(20)38632-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Mast N, Anderson KW, Lin JB, Li Y, Turko IV, Tatsuoka C, Bjorkhem I, Pikuleva IA: Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum. J Biol Chem, 2017; 292: 4913-4924","DOI":"10.1074\/jbc.M116.774760"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Babiker A, Andersson O, Lund E, Xiu RJ, Deeb S, Reshef A, Leitersdorf E, Diczfalusy U, Bj\u00f6rkhem I: Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem, 1997; 272: 26253-26261","DOI":"10.1074\/jbc.272.42.26253"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) von Bahr S, Movin T, Papadogiannakis N, Pikuleva I, R\u00f6nnow P, Diczfalusy U, Bj\u00f6rkhem I: Mechanism of accumulation of cholesterol and cholestanol in tendons and the role of sterol 27-hydroxylase (CYP27A1). Arterioscler Thromb Vasc Biol, 2002; 22: 1129-1135","DOI":"10.1161\/01.ATV.0000022600.61391.A5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Bj\u00f6rkhem I, Andersson O, Diczfalusy U, Sevastik B, Xiu RJ, Duan C, Lund E: Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci U S A, 1994; 91: 8592-8596","DOI":"10.1073\/pnas.91.18.8592"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG: 27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells. J Biol Chem, 2001; 276: 38378-38387","DOI":"10.1074\/jbc.M105805200"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Tall AR, Costet P, Wang N: Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest, 2002; 110: 899-904","DOI":"10.1172\/JCI0216391"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Marengo B, Bellora F, Ricciarelli R, De Ciucis C, Furfaro A, Leardi R, Colla R, Pacini D, Traverso N, Moretta A, Pronzato MA, Bottino C, Domenicotti C: Oxysterol mixture and, in particular, 27-hydroxycholesterol drive M2 polarization of human macrophages. Biofactors, 2016; 42: 80-92","DOI":"10.1002\/biof.1243"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Lorincz MT, Rainier S, Thomas D, Fink JK: Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol, 2005; 62: 1459-1463","DOI":"10.1001\/archneur.62.9.1459"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Appadurai V, DeBarber A, Chiang PW, Patel SB, Steiner RD, Tyler C, Bonnen PE: Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab, 2015; 116: 298-304","DOI":"10.1016\/j.ymgme.2015.10.010"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Berginer VM, Abeliovich D: Genetics of cerebrotendinous xanthomatosis (CTX): an autosomal recessive trait with high gene frequency in Sephardim of Moroccan origin. Am J Med Genet, 1981; 10: 151-157","DOI":"10.1002\/ajmg.1320100209"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Falik-Zaccai TC, Kfir N, Frenkel P, Cohen C, Tanus M, Mandel H, Shihab S, Morkos S, Aaref S, Summar ML, Khayat M: Population screening in a Druze community: the challenge and the reward. Genet Med, 2008; 10: 903-909","DOI":"10.1097\/GIM.0b013e31818d0e0f"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Cali JJ, Russell DW: Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem, 1991; 266: 7774-7778","DOI":"10.1016\/S0021-9258(20)89517-9"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Leitersdorf E, Reshef A, Meiner V, Levitzki R, Schwartz SP, Dann EJ, Berkman N, Cali JJ, Klapholz L, Berginer VM: Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin. J Clin Invest, 1993; 91: 2488-2496","DOI":"10.1172\/JCI116484"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Gallus GN, Dotti MT, Federico A: Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci, 2006; 27: 143-149","DOI":"10.1007\/s10072-006-0618-7"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Chen SF, Tsai NW, Chang CC, Lu CH, Huang CR, Chuang YC, Chang WN: Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis. BMC Neurol, 2011; 11: 63","DOI":"10.1186\/1471-2377-11-63"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Verrips A, Nijeholt GJ, Barkhof F, Van Engelen BG, Wesseling P, Luyten JA, Wevers RA, Stam J, Wokke JH, van den Heuvel LP, Keyser A, Gabre\u00ebls FJ: Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain, 1999; 122: 1589-1595","DOI":"10.1093\/brain\/122.8.1589"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Bartholdi D, Zumsteg D, Verrips A, Wevers RA, Sistermans E, Hess K, Jung HH: Spinal phenotype of cerebrotendinous xanthomatosis--a pitfall in the diagnosis of multiple sclerosis. J Neurol, 2004; 251: 105-107","DOI":"10.1007\/s00415-004-0221-x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Nicholls Z, Hobson E, Martindale J, Shaw PJ: Diagnosis of spinal xanthomatosis by next-generation sequencing: identifying a rare, treatable mimic of hereditary spastic paraparesis. Pract Neurol, 2015; 15: 280-283","DOI":"10.1136\/practneurol-2015-001117"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Saute JA, Giugliani R, Merkens LS, Chiang JP, DeBarber AE, de Souza CF: Look carefully to the heels! A potentially treatable cause of spastic paraplegia. J Inherit Metab Dis, 2015; 38: 363-364","DOI":"10.1007\/s10545-014-9745-0"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Abe R, Sekijima Y, Kinoshita T, Yoshinaga T, Koyama S, Kato T, Ikeda SI: Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion. J Spinal Cord Med, 2016; 39: 726-729","DOI":"10.1179\/1079026815Z.000000000409"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Yanagihashi M, Kano O, Terashima T, Kawase Y, Hanashiro S, Sawada M, Ishikawa Y, Shiraga N, Ikeda K, Iwasaki Y: Late-onset spinal form xanthomatosis without brain lesion: a case report. BMC Neurol, 2016; 16: 21","DOI":"10.1186\/s12883-016-0542-2"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Mutlu D, Tuncer A, Gocmen R, Yalcin-Cakmakli G, Sayg\u0131 S, Elibol B: Diagnostic challenge: A case of late-onset spinal form cerebrotendinous xanthomatosis. Neurology, 2019; 92: 438-439","DOI":"10.1212\/WNL.0000000000007015"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R: Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis, 2002; 25: 501-513","DOI":"10.1023\/A:1021211520034"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) von Bahr S, Bj\u00f6rkhem I, Van\u2019t Hooft F, Alvelius G, Nemeth A, Sj\u00f6vall J, Fischler B: Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy. J Pediatr Gastroenterol Nutr, 2005; 40: 481-486","DOI":"10.1097\/01.MPG.0000150419.23031.2A"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P: Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis, 2008; 31: S241-245","DOI":"10.1007\/s10545-008-0815-z"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Gong JY, Setchell KDR, Zhao J, Zhang W, Wolfe B, Lu Y, Lackner K, Knisely AS, Wang NL, Hao CZ, Zhang MH, Wang JS: Severe Neonatal Cholestasis in Cerebrotendinous Xanthomatosis: Genetics, Immunostaining, Mass Spectrometry. J Pediatr Gastroenterol Nutr, 2017; 65: 561-568","DOI":"10.1097\/MPG.0000000000001730"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Sundaram SS, Bove KE, Lovell MA, Sokol RJ: Mechanisms of disease: Inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol, 2008; 5: 456-468","DOI":"10.1038\/ncpgasthep1179"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Edwards PA, Kast HR, Anisfeld AM: BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res, 2002; 43: 2-12","DOI":"10.1016\/S0022-2275(20)30180-2"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Degos B, Nadjar Y, Amador Mdel M, Lamari F, Sedel F, Roze E, Couvert P, Mochel F: Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood. Orphanet J Rare Dis, 2016; 11: 41","DOI":"10.1186\/s13023-016-0419-x"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) van Heijst AF, Wevers RA, Tangerman A, Cruysberg JR, Renier WO, Tolboom JJ: Chronic diarrhoea as a dominating symptom in two children with cerebrotendinous xanthomatosis. Acta Paediatr, 1996; 85: 932-936","DOI":"10.1111\/j.1651-2227.1996.tb14189.x"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) McKenna P, Morgan SJ, Bosanquet RC, Laker MF: A case of cerebrotendinous xanthomatosis. II: The sterol content of a cataractous lens. Br J Ophthalmol, 1990; 74: 629-630","DOI":"10.1136\/bjo.74.10.629"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Tibrewal S, Duell PB, DeBarber AE, Loh AR: Cerebrotendinous xanthomatosis: early diagnosis on the basis of juvenile cataracts. J AAPOS, 2017; 21: 505-507","DOI":"10.1016\/j.jaapos.2017.07.211"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Freedman SF, Brennand C, Chiang J, DeBarber A, Del Monte MA, Duell PB, Fiorito J, Marshall R: Prevalence of Cerebrotendinous Xanthomatosis Among Patients Diagnosed With Acquired Juvenile-Onset Idiopathic Bilateral Cataracts. JAMA Ophthalmol, 2019; Epub ahead of print","DOI":"10.1001\/jamaophthalmol.2019.3639"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Dotti MT, Rufa A, Federico A: Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings. J Inherit Metab Dis, 2001; 24: 696-706","DOI":"10.1023\/A:1012981019336"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Miyamoto M, Ishii N, Mochizuki H, Shiomi K, Kaida T, Chuman H, Nakazato M: Optic Neuropathy with Features Suggestive of Optic Neuritis in Cerebrotendinous Xanthomatosis. Case Rep Neurol Med, 2019; 2019: 2576826","DOI":"10.1155\/2019\/2576826"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis HJ: Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands. Clin Neurol Neurosurg, 1987; 89: 169-175","DOI":"10.1016\/S0303-8467(87)80050-1"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Dotti MT, Salen G, Federico A: Cerebrotendinous xanthomatosis as a multisystem disease mimicking premature ageing. Dev Neurosci, 1991; 13: 371-376","DOI":"10.1159\/000112187"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Tian D, Zhang ZQ: 2 Novel deletions of the sterol 27-hydroxylase gene in a Chinese Family with Cerebrotendinous Xanthomatosis. BMC Neurol, 2011; 11: 130","DOI":"10.1186\/1471-2377-11-130"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Varman KM, Dunbar K, Usifo K, Stevens CA: Cerebrotendinous Xanthomatosis: A Treatable Genetic Disease Not to Be Missed. J Clin Rheumatol, 2016; 22: 92-93","DOI":"10.1097\/RHU.0000000000000367"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Koopal C, Visseren FL, Marais AD, Westerink J, Spiering W: Tendon xanthomas: Not always familial hypercholesterolemia. J Clin Lipidol, 2016; 10: 1262-1265","DOI":"10.1016\/j.jacl.2016.05.005"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Sperhake JP, Matschke J, Orth U, Gal A, P\u00fcschel K: Sudden death due to cerebrotendinous xanthomatosis confirmed by mutation analysis. Int J Legal Med, 2000; 113: 110-113","DOI":"10.1007\/PL00007709"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Vanrietvelde F, Lemmerling M, Mespreuve M, Crevits L, De Reuck J, Kunnen M: MRI of the brain in cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease). Eur Radiol, 2000; 10: 576-578","DOI":"10.1007\/s003300050964"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Brienza M, Fiermonte G, Cambieri C, Mignarri A, Dotti MT, Fiorelli M: Enlarging brain xanthomas in a patient with cerebrotendinous xanthomatosis. J Inherit Metab Dis, 2015; 38: 981-982","DOI":"10.1007\/s10545-014-9805-5"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Verrips A, van Engelen BG, Wevers RA, van Gee Mondelli l BM, Cruysberg JR, van den Heuvel LP, Keyser A, Gabre\u00ebls FJ: Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. Arch Neurol, 2000; 57: 520-524","DOI":"10.1001\/archneur.57.4.520"},{"key":"69","doi-asserted-by":"publisher","unstructured":"69) Jain RS, Sannegowda RB, Agrawal A, Hemrajani D, Jain R, Mathur T: \u2018Hot cross bun\u2019 sign in a case of cerebrotendinous xanthomatosis: a rare neuroimaging observation. BMJ Case Rep, 2013; doi: 10.1136\/bcr-2012-006641","DOI":"10.1136\/bcr-2012-006641"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Okada J, Oonishi H, Tamada H, Kizaki T, Yasumi K, Matuo T: Gallium uptake in cerebrotendinous xanthomatosis. Eur J Nucl Med, 1995; 22: 1069-1072","DOI":"10.1007\/BF00808420"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Nakamura T, Matsuzawa Y, Takemura K, Kubo M, Miki H, Tarui S: Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism, 1991; 40: 741-746","DOI":"10.1016\/0026-0495(91)90094-D"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Mondelli M, Sicurelli F, Scarpini C, Dotti MT, Federico A: Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study. J Neurol Sci, 2001; 190: 29-33","DOI":"10.1016\/S0022-510X(01)00563-9"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Berginer VM, Shany S, Alkalay D, Berginer J, Dekel S, Salen G, Tint GS, Gazit D: Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism, 1993; 42: 69-74","DOI":"10.1016\/0026-0495(93)90174-M"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Martini G, Mignarri A, Ruvio M, Valenti R, Franci B, Del Puppo M, Federico A, Nuti R, Dotti MT: Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int, 2013; 92: 282-286","DOI":"10.1007\/s00223-012-9677-3"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Z\u00fcbario\u011flu T, Bilen \u0130P, K\u0131yk\u0131m E, Do\u011fan BB, Enver E\u00d6, Cansever M\u015e, Zeybek A\u00c7A: Evaluation of the effect of chenodeoxycholic acid treatment on skeletal system findings in patients with cerebrotendinous xanthomatosis. Turk Pediatri Ars, 2019; 54: 113-118","DOI":"10.14744\/TurkPediatriArs.2019.23281"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Federico A, Dotti MT, Lor\u00e9 F, Nuti R: Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. J Neurol Sci, 1993; 115: 67-70","DOI":"10.1016\/0022-510X(93)90068-A"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Zubarioglu T, Kiykim E, Yesil G, Demircioglu D, Cansever MS, Yalcinkaya C, Aktuglu-Zeybek C: Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey. Acta Neurol Belg, 2019; 119: 343-350","DOI":"10.1007\/s13760-017-0851-2"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Ginanneschi F, Mignarri A, Mondelli M, Gallus GN, Del Puppo M, Giorgi S, Federico A, Rossi A, Dotti MT: Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J Neurol, 2013; 260: 268-274","DOI":"10.1007\/s00415-012-6630-3"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Kuriyama M, Fujiyama J, Yoshidome H, Takenaga S, Matsumuro K, Kasama T, Fukuda K, Kuramoto T, Hoshita T, Seyama Y, Okatu Y, Osame M: Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. J Neurol Sci, 1991; 102: 225-232","DOI":"10.1016\/0022-510X(91)90073-G"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Fujiyama J, Kuriyama M, Arima S, Shibata Y, Nagata K, Takenaga S, Tanaka H, Osame M: Atherogenic risk factors in cerebrotendinous xanthomatosis. Clin Chim Acta, 1991; 200: 1-11","DOI":"10.1016\/0009-8981(91)90328-A"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Burnett JR, Moses EA, Croft KD, Brown AJ, Grainger K, Vasikaran SD, Leitersdorf E, Watts GF: Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clin Chim Acta, 2001; 306: 63-69","DOI":"10.1016\/S0009-8981(01)00391-6"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Valdivielso P, Calandra S, Dur\u00e1n JC, Garuti R, Herrera E, Gonz\u00e1lez P: Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J Intern Med, 2004; 255: 680-683","DOI":"10.1111\/j.1365-2796.2004.01316.x"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Tada H, Inaba S, Pozharitckaia D, Kawashiri MA: Prominent Tendon Xanthomas and Abdominal Aortic Aneurysm Associated with Cerebrotendinous Xanthomatosis Identified Using Whole Exome Sequencing. Intern Med, 2018; 57: 1119-1122","DOI":"10.2169\/internalmedicine.9687-17"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Souto MJS, Almeida-Santos MA, Ferreira EJP, Gon\u00e7alves LFG, Oliveira JLM, Sousa ACS: Spontaneous Coronary Artery Dissection in a Patient with Cerebrotendinous Xanthomatosis. Arq Bras Cardiol, 2020; 115: 18-21","DOI":"10.36660\/abc.20190456"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Potkin BN, Hoeg JM, Connor WE, Salen G, Quyyumi AA, Brush JE Jr, Roberts WC, Brewer HB Jr: Aneurysmal coronary artery disease in cerebrotendinous xanthomatosis. Am J Cardiol, 1988; 61: 1150-1152","DOI":"10.1016\/0002-9149(88)90155-5"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Dotti MT, Mondillo S, Plewnia K, Agricola E, Federico A: Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum. J Neurol, 1998; 245: 723-726","DOI":"10.1007\/s004150050274"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Kawabata M, Kuriyama M, Mori S, Sakashita I, Osame M: Pulmonary manifestations in cerebrotendinous xanthomatosis. Intern Med, 1998; 37: 922-926","DOI":"10.2169\/internalmedicine.37.922"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Guyant-Mar\u00e9chal L, Verrips A, Girard C, Wevers RA, Zijlstra F, Sistermans E, Vera P, Campion D, Hannequin D: Unusual cerebrotendinous xanthomatosis with fronto-temporal dementia phenotype. Am J Med Genet A, 2005; 139A: 114-117","DOI":"10.1002\/ajmg.a.30797"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Mukaino A, Tsuda M, Yamashita S, Kosaka T, Wada K, Ando Y: Cerebrotendinous xanthomatosis presenting with extensive cerebral cortex symptoms: A case report. Clin Neurol Neurosurg, 2018; 174: 217-219","DOI":"10.1016\/j.clineuro.2018.09.028"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Rubio-Agusti I, Kojovic M, Edwards MJ, Murphy E, Chandrashekar HS, Lachmann RH, Bhatia KP: Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord, 2012; 27: 1769-1774","DOI":"10.1002\/mds.25229"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Mignarri A, Rossi S, Ballerini M, Gallus GN, Del Puppo M, Galluzzi P, Federico A, Dotti MT: Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol, 2011; 258: 783-790","DOI":"10.1007\/s00415-010-5829-4"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Siebner HR, Berndt S, Conrad B: Cerebrotendinous xanthomatosis without tendon xanthomas mimicking Marinesco-Sjoegren syndrome: a case report. J Neurol Neurosurg Psychiatry, 1996; 60: 582-585","DOI":"10.1136\/jnnp.60.5.582"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Ly H, Bertorini TE, Shah N: An adult male with progressive spastic paraparesis and gait instability. J Clin Neuromuscul Dis, 2014; 16: 98-103","DOI":"10.1097\/CND.0000000000000058"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Alhariri A, Hamilton K, Oza V, Cordoro K, Sobreira NL, Malloy M, Slavotinek A: Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment. Am J Med Genet A, 2017; 173: 2275-2279","DOI":"10.1002\/ajmg.a.38314"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Su CS, Chang WN, Huang SH, Lui CC, Pan TL, Lu CH, Chuang YC, Huang CR, Tsai NW, Hsieh MJ, Chang CC: Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord, 2010; 25: 452-458","DOI":"10.1002\/mds.22979"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Kirmi O, Murphy E, Carecchio M, Sulkin T, Rankin J, Robertson F: Teaching neuroimages: progressive asymmetric parkinsonism and tendon xanthomas. Neurology, 2011; 77: e97-98","DOI":"10.1212\/WNL.0b013e318234325e"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Posada IJ, Ramos A: Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord, 2011; 17: 570-572","DOI":"10.1016\/j.parkreldis.2011.04.006"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Lagarde J, Roze E, Apartis E, Pothalil D, Sedel F, Couvert P, Vidailhet M, Degos B: Myoclonus and dystonia in cerebrotendinous xanthomatosis. Mov Disord, 2012; 27: 1805-1810","DOI":"10.1002\/mds.25206"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Yoshinaga T, Sekijima Y, Koyama S, Maruyama K, Yoshida T, Kato T, Ikeda S: Clinical and radiological findings of a cerebrotendinous xanthomatosis patient with a novel p.A335V mutation in the CYP27A1 gene. Intern Med, 2014; 53: 2725-2729","DOI":"10.2169\/internalmedicine.53.2996"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Szlago M, Gallus GN, Schenone A, Pati\u00f1o ME, Sfaelo Z, Rufa A, Da Pozzo P, Cardaioli E, Dotti MT, Federico A: The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. Neurology, 2008; 70: 402-404","DOI":"10.1212\/01.wnl.0000280460.28039.3d"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Dutta AK, Danda S, Muthusamy K, Alexander M, Sudhakar SV, Hansdak S, Bandyopadhyay R, Bakhya Shree GB, Rekha L: Cerebrotendinous xanthomatosis: Possibility of founder mutation in CYP27A1 gene (c.526delG) in Eastern Indian and Surinamese population. Mol Genet Metab Rep, 2015; 3: 33-35","DOI":"10.1016\/j.ymgmr.2015.03.002"},{"key":"102","unstructured":"102) Isenhardt K, Schmitt R, Nagel A, Drach L, Schlote W: Inherited cholesterol lipidosis: cerebrotendinous xanthomatosis (van Bogaert Scherer Epstein disease). A clinicopathological study. Clin Neuropathol, 2005; 24: 276-283"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Stelten BML, van de Warrenburg BPC, Wevers RA, Verrips A: Movement disorders in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord, 2019; 58: 12-16","DOI":"10.1016\/j.parkreldis.2018.07.006"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Mignarri A, Falcini M, Vella A, Giorgio A, Gallus GN, Del Puppo M, Vattimo A, Federico A, Dotti MT: Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. Parkinsonism Relat Disord, 2012; 18: 99-101","DOI":"10.1016\/j.parkreldis.2011.06.004"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Schotsmans K, De Cauwer H, Baets J, Ceyssens S, van den Hauwe L, Deconinck T, Helsen G: Cerebrotendinous xanthomatosis presenting with asymmetric parkinsonism: a case with I-123-FP-CIT SPECT imaging. Acta Neurol Belg, 2012; 112: 287-289","DOI":"10.1007\/s13760-012-0064-7"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Ohnishi A, Yamashita Y, Goto I, Kuroiwa Y, Murakami S, Ikeda M: De- and remyelination and onion bulb in cerebrotendinous xanthomatosis. Acta Neuropathol, 1979; 45: 43-45","DOI":"10.1007\/BF00691803"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Argov Z, Soffer D, Eisenberg S, Zimmerman Y: Chronic demyelinating peripheral neuropathy in cerebrotendinous xanthomatosis. Ann Neurol, 1986; 20: 89-91","DOI":"10.1002\/ana.410200115"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Verrips A, van Engelen BG, ter Laak H, Gabre\u00ebls-Festen A, Janssen A, Zwarts M, Wevers RA, Gabre\u00ebls FJ: Cerebrotendinous xanthomatosis. Controversies about nerve and muscle: observations in ten patients. Neuromuscul Disord, 2000; 10: 407-414","DOI":"10.1016\/S0960-8966(00)00112-7"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Pilo B, de Blas G, Sobrido MJ, Navarro C, Grandas F, Barrero FJ, Moya MA, Jimenez-Escrig A: Neurophysiological study in cerebrotendinous xanthomatosis. Muscle Nerve, 2011; 43: 531-536","DOI":"10.1002\/mus.21905"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Wang Z, Yuan Y, Zhang W, Zhang Y, Feng L: Cerebrotendinous xanthomatosis with a compound heterozygote mutation and severe polyneuropathy. Neuropathology, 2007; 27: 62-66","DOI":"10.1111\/j.1440-1789.2006.00739.x"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Hashimoto T, Sennari Y, Okada K, Adachi H: Cerebrotendinous Xanthomatosis with Nodular-hypertrophy of the Lumbosacral Roots. Intern Med, 2018; 57: 1669-1670","DOI":"10.2169\/internalmedicine.9883-17"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Federico A, Dotti MT, Volpi N: Muscle mitochondrial changes in cerebrotendinous xanthomatosis. Ann Neurol, 1991; 30: 734-735","DOI":"10.1002\/ana.410300517"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Dotti MT, Manneschi L, Federico A: Mitochondrial enzyme deficiency in cerebrotendinous xanthomatosis. J Neurol Sci, 1995; 129: 106-108","DOI":"10.1016\/0022-510X(94)00256-N"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Arlazoroff A, Roitberg B, Werber E, Shidlo R, Berginer VM: Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. Epilepsia, 1991; 32: 657-661","DOI":"10.1111\/j.1528-1157.1991.tb04705.x"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Koyama S, Kawanami T, Tanji H, Arawaka S, Wada M, Saito N, Kato T: A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene. Clin Neurol Neurosurg, 2012; 114: 1021-1023","DOI":"10.1016\/j.clineuro.2012.01.032"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Pedroso JL, Pinto WB, Souza PV, Santos LT, Abud IC, Avelino MA, Barsottini OG: Early-onset epilepsy as the main neurological manifestation of cerebrotendinous xanthomatosis. Epilepsy Behav, 2012; 24: 380-381","DOI":"10.1016\/j.yebeh.2012.04.121"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Larson A, Weisfeld-Adams JD, Benke TA, Bonnen PE: Cerebrotendinous Xanthomatosis Presenting with Infantile Spasms and Intellectual Disability. JIMD Rep, 2017; 35: 1-5","DOI":"10.1007\/8904_2016_16"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Berginer VM, Radwan H, Korczyn AD, Kott E, Salen G, Shefer S: EEG in cerebrotendinous xanthomatosis (CTX). Clin Electroencephalogr, 1982; 13: 89-96","DOI":"10.1177\/155005948201300204"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Wakamatsu N, Hayashi M, Kawai H, Kondo H, Gotoda Y, Nishida Y, Kondo R, Tsuji S, Matsumoto T: Mutations producing premature termination of translation and an amino acid substitution in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis associated with parkinsonism. J Neurol Neurosurg Psychiatry, 1999; 67: 195-198","DOI":"10.1136\/jnnp.67.2.195"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Catarino CB, Vollmar C, K\u00fcpper C, Seelos K, Gallenm\u00fcller C, Bartkiewicz J, Biskup S, H\u00f6rtnagel K, Klopstock T: Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment. J Neurol, 2018; 265: 388-393","DOI":"10.1007\/s00415-017-8711-9"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Kauffman MA, Gonzalez-Mor\u00f3n D, Consalvo D, Kochen S: Cerebrotendinous xanthomatosis revealed in drug-resistant epilepsy diagnostic workup. Am J Med Sci, 2012; 343: 332-333","DOI":"10.1097\/MAJ.0b013e31823cf6d8"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122) Fraidakis MJ: Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry, 2013; 3: e302","DOI":"10.1038\/tp.2013.76"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) De Stefano N, Dotti MT, Mortilla M, Federico A: Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain, 2001; 124: 121-131","DOI":"10.1093\/brain\/124.1.121"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Barkhof F, Verrips A, Wesseling P, van Der Knaap MS, van Engelen BG, Gabre\u00ebls FJ, Keyser A, Wevers RA, Valk J: Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology, 2000; 217: 869-876","DOI":"10.1148\/radiology.217.3.r00dc03869"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125) Ahmed RM, Murphy E, Davagnanam I, Parton M, Schott JM, Mummery CJ, Rohrer JD, Lachmann RH, Houlden H, Fox NC, Chataway J: A practical approach to diagnosing adult onset leukodystrophies. J Neurol Neurosurg Psychiatry, 2014; 85: 770-781","DOI":"10.1136\/jnnp-2013-305888"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126) Guerrera S, Stromillo ML, Mignarri A, Battaglini M, Marino S, Di Perri C, Federico A, Dotti MT, De Stefano N: Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry, 2010; 81: 1189-1193","DOI":"10.1136\/jnnp.2009.203364"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) Mandia, Besson G, Lamari F, Castelnovo G, Curot J, Duval F, Giral P, Lecerf JM, Roland D, Pierdet H, Douillard C, Nadjar Y: Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol, 2019; 266: 2043-2050","DOI":"10.1007\/s00415-019-09377-y"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128) Mignarri A, Dotti MT, Federico A, De Stefano N, Battaglini M, Grazzini I, Galluzzi P, Monti L: The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. J Neurol, 2017; 264: 862-874","DOI":"10.1007\/s00415-017-8440-0"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129) Embiru\u00e7u EK, Otaduy MC, Taneja AK, Leite CC, Kok F, Lucato LT: MR spectroscopy detects lipid peaks in cerebrotendinous xanthomatosis. Am J Neuroradiol, 2010; 31: 1347-1349","DOI":"10.3174\/ajnr.A1885"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130) Mignarri A, Dotti MT, Del Puppo M, Gallus GN, Giorgio A, Cerase A, Monti L: Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation: six-year MRI follow-up. Neuroradiology, 2012; 54: 649-651","DOI":"10.1007\/s00234-012-1026-8"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131) Ragno M, Di Marzio F, Fuccio C, Pianese L, Cozzolino V, Carboni T, Cinti A, D\u2019Andreamatteo G, Trojano L, Mignarri A, Gallus GN, Dotti MT: Cerebellar hypometabolism with normal structural findings in Cerebrotendinous xanthomatosis. A case report. Clin Neurol Neurosurg, 2015; 139: 221-223","DOI":"10.1016\/j.clineuro.2015.10.020"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132) Caroppo P, D\u2019Agata F, Mignarri A, Stromillo ML, Dotti MT, Mongini T: Brain metabolism changes after therapy with chenodeoxycholic acid in a case of cerebrotendinous xanthomatosis. Neurol Sci, 2013; 34: 1693-1696","DOI":"10.1007\/s10072-012-1262-z"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133) Chang CC, Lui CC, Wang JJ, Huang SH, Lu CH, Chen C, Chen CF, Tu MC, Huang CW, Chang WN: Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations. BMC Neurol, 2010; 10: 59","DOI":"10.1186\/1471-2377-10-59"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134) Seidel S, Kasprian G, Prayer D, Krss\u00e1k M, Sycha T, Auff E: Visualisation of treatment response in a case of cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry, 2011; 82: 703-704","DOI":"10.1136\/jnnp.2009.196444"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135) Soffer D, Benharroch D, Berginer V: The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol, 1995; 90: 213-220","DOI":"10.1007\/BF00294324"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136) Kato H, Koyabu S, Aoki S, Tamai T, Sugawa M, Watanabe M, Shiraishi T: An autopsy case of gallbladder cancer developing in a Japanese man with cerebrotendinous xanthomatosis: genetic analysis of the sterol 27-hydroxylase and p53 genes. Pathology, 2003; 35: 141-144","DOI":"10.1097\/01268031-200335020-00008"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137) Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A: Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol, 2008; 255: 839-842","DOI":"10.1007\/s00415-008-0729-6"},{"key":"138","unstructured":"138) Isenhardt K, Schmitt R, Nagel A, Drach L, Schlote W: Inherited cholesterol lipidosis: cerebrotendinous xanthomatosis (van Bogaert Scherer Epstein disease). A clinicopathological study. Clin Neuropathol, 2005; 24: 276-283"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139) Wallon D, Guyant-Mar\u00e9chal L, Laquerri\u00e8re A, Wevers RA, Martinaud O, Kluijtmans LA, Yntema HG, Saugier-Veber P, Hannequin D: Clinical imaging and neuropathological correlations in an unusual case of cerebrotendinous xanthomatosis. Clin Neuropathol, 2010; 29: 361-364","DOI":"10.5414\/NPP29361"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140) Tokimura Y, Kuriyama M, Arimura K, Fujiyama J, Osame M: Electrophysiological studies in cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry, 1992; 55: 52-55","DOI":"10.1136\/jnnp.55.1.52"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141) Mondelli M, Rossi A, Scarpini C, Dotti MT, Federico A: Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid. Arch Neurol, 1992; 49: 469-475","DOI":"10.1001\/archneur.1992.00530290051011"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142) Berginer VM, Gross B, Morad K, Kfir N, Morkos S, Aaref S, Falik-Zaccai TC: Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics, 2009; 123: 143-147","DOI":"10.1542\/peds.2008-0192"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143) Cruysberg JR, Wevers RA, Tolboom JJ: Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthalmol, 1991; 112: 606-607","DOI":"10.1016\/S0002-9394(14)76874-6"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144) Sundaram SS, Bove KE, Lovell MA, Sokol RJ: Mechanisms of disease: Inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol, 2008; 5: 456-468","DOI":"10.1038\/ncpgasthep1179"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145) Clayton PT: Disorders of bile acid synthesis. J Inherit Metab Dis, 2011; 34: 593-604","DOI":"10.1007\/s10545-010-9259-3"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146) Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med, 2007; 4: 214-225","DOI":"10.1038\/ncpcardio0836"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147) Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA: Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. J Atheroscler Thromb, 2018; 25: 783-789","DOI":"10.5551\/jat.RV17024"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148) Salen G, Batta AK, Tint GS, Shefer S: Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. Metabolism, 1994; 43: 1018-1022","DOI":"10.1016\/0026-0495(94)90183-X"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149) Verrips A, Wevers RA, Van Engelen BG, Keyser A, Wolthers BG, Barkhof F, Stalenhoef A, De Graaf R, Janssen-Zijlstra F, Van Spreeken A, Gabre\u00ebls FJ: Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism, 1999; 48: 233-238","DOI":"10.1016\/S0026-0495(99)90040-9"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150) Kuriyama M, Tokimura Y, Fujiyama J, Utatsu Y, Osame M: Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci, 1994; 125: 22-28","DOI":"10.1016\/0022-510X(94)90237-2"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151) Huidekoper HH, Vaz FM, Verrips A, Bosch AM: Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment. Eur J Pediatr, 2016; 175: 143-146","DOI":"10.1007\/s00431-015-2584-7"},{"key":"152","doi-asserted-by":"crossref","unstructured":"152) Ellis E, Axelson M, Abrahamsson A, Eggertsen G, Th\u00f6rne A, Nowak G, Ericzon BG, Bj\u00f6rkhem I, Einarsson C: Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology, 2003; 38: 930-938","DOI":"10.1002\/hep.1840380419"},{"key":"153","doi-asserted-by":"crossref","unstructured":"153) Setchell KD, Heubi JE: Defects in bile acid biosynthesis--diagnosis and treatment. J Pediatr Gastroenterol Nutr, 2006; 43: S17-22","DOI":"10.1097\/01.mpg.0000226386.79483.7b"},{"key":"154","doi-asserted-by":"crossref","unstructured":"154) Batta AK, Salen G, Tint GS: Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis. Metabolism, 2004; 53: 556-562","DOI":"10.1016\/j.metabol.2003.12.003"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155) Lewis B, Mitchell WD, Marenah CB, Cortese C, Reynolds EH, Shakir R: Cerebrotendinous xanthomatosis: biochemical response to inhibition of cholesterol synthesis. Br Med J (Clin Res Ed), 1983; 287: 21-22","DOI":"10.1136\/bmj.287.6384.21-a"},{"key":"156","doi-asserted-by":"crossref","unstructured":"156) Luyckx E, Eyskens F, Simons A, Beckx K, Van West D, Dhar M: Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report. Clin Neurol Neurosurg, 2014; 118: 9-11","DOI":"10.1016\/j.clineuro.2013.12.008"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157) Mimura Y, Kuriyama M, Tokimura Y, Fujiyama J, Osame M, Takesako K, Tanaka N: Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis. J Neurol Sci, 1993; 114: 227-230","DOI":"10.1016\/0022-510X(93)90303-G"},{"key":"158","doi-asserted-by":"crossref","unstructured":"158) Ito S, Kuwabara S, Sakakibara R, Oki T, Arai H, Oda S, Hattori T: Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci, 2003; 216: 179-182","DOI":"10.1016\/j.jns.2003.07.005"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159) Dotti MT, L\u00fctjohann D, von Bergmann K, Federico A: Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis. Neurol Sci, 2004; 25: 185-191","DOI":"10.1007\/s10072-004-0320-6"},{"key":"160","doi-asserted-by":"crossref","unstructured":"160) Matysik S, Ors\u00f3 E, Black A, Ahrens N, Schmitz G: Monitoring of 7\u03b1-hydroxy-4-cholesten-3-one during therapy of cerebrotendinous xanthomatosis: a case report. Chem Phys Lipids, 2011; 164: 530-534","DOI":"10.1016\/j.chemphyslip.2011.05.001"},{"key":"161","doi-asserted-by":"crossref","unstructured":"161) Berginer VM, Salen G: LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis. J Neurol Sci, 1994; 121: 229-232","DOI":"10.1016\/0022-510X(94)90357-3"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162) Selva-O\u2019Callaghan A, Bardes I, Jacas C, Jubany L, Lorenzo-Bosquet C, Cuberas-Borr\u00f3s G, Vilardell-Tarres M: SPECT imaging for brain improvement quantification in a patient with cerebrotendinous xanthomatosis. Clin Nucl Med, 2011; 36: 38-39","DOI":"10.1097\/RLU.0b013e3181feed83"},{"key":"163","doi-asserted-by":"crossref","unstructured":"163) Amador MDM, Masingue M, Debs R, Lamari F, Perlbarg V, Roze E, Degos B, Mochel F: Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes. J Inherit Metab Dis, 2018; 41: 799-807","DOI":"10.1007\/s10545-018-0162-7"},{"key":"164","doi-asserted-by":"crossref","unstructured":"164) DeBarber AE, Kalfon L, Fedida A, Fleisher Sheffer V, Ben Haroush S, Chasnyk N, Shuster Biton E, Mandel H, Jeffries K, Shinwell ES, Falik-Zaccai TC: Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment. J Lipid Res, 2018; 59: 2214-2222","DOI":"10.1194\/jlr.M087999"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/9\/28_RV17055\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:38:58Z","timestamp":1715143138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/9\/28_RV17055\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":164,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv17055","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"article-number":"RV17055"}}